Evidence map›Paper›PMID 35600114›Full record

ArticleOpen medicine (Warsaw, Poland)2022

Isocitrate dehydrogenase 1 mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis.

Li Su, Yi Huang, Lei Zheng, Zhifa Zhu, Yue Wu, Ping Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. A guide to ferroptosis in cancer.Molecular oncology · 2024
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Li SuDepartment of Integrated Traditional and Western Medicine in Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Yi HuangAnhui University of Traditional Chinese Medicine, Hefei 230012, China.
Lei ZhengDepartment of Integrated Traditional and Western Medicine in Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Zhifa ZhuDepartment of Integrated Traditional and Western Medicine in Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Yue WuDepartment of Integrated Traditional and Western Medicine in Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
Ping LiDepartment of Integrated Traditional and Western Medicine in Oncology, The First Affiliated Hospital of Anhui Medical University, No. 120, Wanshui Road, Hefei 230022, China.
First Affiliated Hospital of Anhui Medical University · CNAnhui Medical University · CNAnhui University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study intends to clarify the hypothesis that isocitrate dehydrogenase 1 (IDH1) mutation in cholangiocarcinoma impairs tumor progression by sensitizing cells to ferroptosis through the

Indexed as

cholangiocarcinomaferroptosisIDH1mutation

Identifiers

PMID35600114
PMCPMC9077397
OpenAlexW4285211020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.